In silico analysis of potential off-target sites to gene editing for Mucopolysaccharidosis type I using the CRISPR/Cas9 system: Implications for population-specific treatments
dc.contributor.author | Carneiro, Paola Barcelos | pt_BR |
dc.contributor.author | Freitas, Martiela Vaz de | pt_BR |
dc.contributor.author | Matte, Ursula da Silveira | pt_BR |
dc.date.accessioned | 2024-03-28T06:23:04Z | pt_BR |
dc.date.issued | 2022 | pt_BR |
dc.identifier.issn | 1932-6203 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/274300 | pt_BR |
dc.description.abstract | Mucopolysaccharidosis type I (MPS I) is caused by alpha-L-iduronidase deficiency encoded by the IDUA gene. Therapy with CRISPR/Cas9 is being developed for treatment, however a detailed investigation of off-target effects must be performed. This study aims to evaluate possible off-targets for a sgRNA aiming to correct the most common variant found in MPS I patients (p.Trp402*). A total of 272 potential off-target sequences was obtained and 84 polymorphic sites were identified in these sequences with a frequency equal to or greater than 1% in at least one of the populations. In the majority of cases, polymorphic sites decrease the chance of off-target cleavage and a new PAM was created, which indicates the importance of such analysis. This study highlights the importance of screening off-targets in a population-specific context using Mucopolysaccharidosis type I as an example of a problem that concerns all therapeutic treatments. Our results can have broader applications for other targets already clinically in use, as they could affect CRISPR/Cas9 safety and efficiency. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | PloS one. San Francisco. Vol. 17, no. 1 (Jan. 2022), e0262299, 13 p. | pt_BR |
dc.rights | Open Access | en |
dc.subject | Alfa-L-iduronidase | pt_BR |
dc.subject | Therapy with CRISPR/Cas9 | en |
dc.title | In silico analysis of potential off-target sites to gene editing for Mucopolysaccharidosis type I using the CRISPR/Cas9 system: Implications for population-specific treatments | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 001162226 | pt_BR |
dc.type.origin | Estrangeiro | pt_BR |
Files in this item
This item is licensed under a Creative Commons License
-
Journal Articles (39559)Biological Sciences (3082)